Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023229 | 1.00 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023228 | 1.00 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023250 | 1.00 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023284 | 0.89 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023285 | 0.89 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023231 | 0.85 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023230 | 0.85 | HCRTR2 (0.67) | HCRTR2GPR119 | |
| SCHEMBL22023234 | 0.84 | HCRTR2 (0.90) | HCRTR2 | |
| SCHEMBL22023233 | 0.84 | HCRTR2 (0.90) | HCRTR2 | |
| SCHEMBL22023240 | 0.83 | HCRTR2 (0.60) | HCRTR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663281-B1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-11319286-B2 | Heterocyclic compound and application thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3663281-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319286-B2 | Heterocyclic compound and application thereof | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885GPR119 28/4885 |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885GPR119 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.